BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34667022)

  • 1. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
    Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
    Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
    Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
    Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
    Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
    Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
    Ten Cate C; Huijs SMH; Willemsen ACH; Pasmans RCOS; Eekers DBP; Zegers CML; Ackermans L; Beckervordersandforth J; van Raak EPM; Anten MHME; Hoeben A; Postma AA; Broen MPG
    J Neurooncol; 2022 Dec; 160(3):611-618. PubMed ID: 36394717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
    An G; Ahn S; Park JS; Jeun SS; Hong YK
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective.
    Sütcüoğlu O; Erdal ZS; Akdoğan O; Çeltikçi E; Özdemir N; Özet A; Uçar M; Yazıcı O
    Turk J Med Sci; 2023 Feb; 53(1):413-419. PubMed ID: 36945944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
    Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation study.
    Broen MPG; Beckers R; Willemsen ACH; Huijs SMH; Pasmans RCOS; Eekers DBP; Ackermans L; Beckervordersandforth J; van Raak EPM; Verduin M; Anten MHME; Hoeben A; Postma AA
    Neurooncol Adv; 2022; 4(1):vdac038. PubMed ID: 35475275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
    Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
    Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma.
    Lee B; Bae YJ; Jeong WJ; Kim H; Choi BS; Kim JH
    Sci Rep; 2021 Oct; 11(1):19717. PubMed ID: 34611230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
    Yesil Cinkir H; Colakoglu Er H
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
    Le Rhun E; Oppong FB; Vanlancker M; Stupp R; Nabors B; Chinot O; Wick W; Preusser M; Gorlia T; Weller M
    Neuro Oncol; 2022 Sep; 24(9):1533-1545. PubMed ID: 35312789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis.
    Sadhwani N; Aggarwal A; Mishra A; Garg K
    Neurosurg Rev; 2022 Dec; 45(6):3619-3628. PubMed ID: 36350492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
    J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis.
    Wende T; Kasper J; Prasse G; Glass Ä; Kriesen T; Freiman TM; Meixensberger J; Henker C
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness.
    Leone R; Sferruzza G; Calimeri T; Steffanoni S; Conte GM; De Cobelli F; Falini A; Ferreri AJM; Anzalone N
    Eur J Radiol; 2021 Oct; 143():109945. PubMed ID: 34492625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
    Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
    J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
    Seliger C; Genbrugge E; Gorlia T; Chinot O; Stupp R; Nabors B; Weller M; Hau P;
    Int J Cancer; 2020 Feb; 146(3):803-809. PubMed ID: 30980539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma.
    Furtner J; Nenning KH; Roetzer T; Gesperger J; Seebrecht L; Weber M; Grams A; Leber SL; Marhold F; Sherif C; Trenkler J; Kiesel B; Widhalm G; Asenbaum U; Woitek R; Berghoff AS; Prayer D; Langs G; Preusser M; Wöhrer A
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy.
    Pasqualetti F; Gabelloni M; Gonnelli A; Faggioni L; Cantarella M; Montrone S; Gadducci G; Giannini N; Montemurro N; Mattioni R; Perrini P; Morganti R; Cosottini M; Neri E; Paiar F
    Radiol Med; 2022 Aug; 127(8):919-924. PubMed ID: 35849309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.